Overview of patients with MF/SS treated with alemtuzumab
Patient no. . | Age/sex . | Previous treatment . | Best response . | Cumulative alemtuzumab dose (mg) . | Previous ANTH . | Cardiac risks before alemtuzumab therapy . | Cardiac toxicity during or after*alemtuzumab therapy . |
|---|---|---|---|---|---|---|---|
| 1 | 73/M | Steroids, interferon, Tigason | CR | 1016 | No | MI 1998, Asthma | None |
| 2 | 73/M | Methotrexate, interferon, photophoresis, chlorambucil, steroids, fludarabine ×5 | PR | 1033 | No | Asthma, chronic bronchitis | None |
| 3 | 77/F | Methotrexate + 5FU ×9, PUVA | CR | 913 | No | HTN, CVL 1996 | None |
| 4 | 60/F | PUVA, CdA ×4, CHOP ×8, radiotherapy | PD | 563 | Yes | None | None |
| 5 | 52/M | Chlorambucil + steroids, fludarabine + cyclophosphamide + steroids | SD | 733 | No | None | None |
| 6 | 61/M | PUVA-photophoresis, α-IFN, methotrexate | CR | 1023 | No | None | None |
| 7 | 49/F | Local skin treatment | PR | 968 | No | None | None |
| 8 | 65/F | Methotrexate, steroids | CR | 334 | No | Cardiomyopathy | None |
| 9 | 72/F | PUVA, radiotherapy | PR | 1063 | No | None | None |
| 10 | 55/M | PUVA, steroids | PR | 1033 | No | None | None |
| 11 | 63/M | CHOP ×5, radiotherapy | PD | 373 | Yes | None | None |
| 12 | 77/F | Radiotherapy, vitamin A, PUVA, α-IFN, methotrexate | SD | 313 | No | Angina pectoris | None |
| 13 | 62/F | PUVA, photophoresis, steroids | CR | 876 | No | None | None |
| 14 | 63/F | PUVA, α-IFN, chlorambucil + steroids | CR | 1035 | No | None | None |
| 15 | 60/F | Chlorambucil + steroids, CHOP ×4, photophoresis | PD | 756 | Yes | CHF, nonsymptomatic mitral insuffiency | None |
| 16 | 56/M | PUVA, radiotherapy | CR | 1033 | No | None | None |
| 17 | 71/F | PUVA, photophoresis | PR | 1033 | No | Unknown | None† |
| 18 | 57/M | PUVA, steroids, methotrexate | PD | 1033 | No | None | None† |
| 19 | 56/F | Radiotherapy, α-IFN, chlorambucil + steroids, methotrexate | PD | 253 | No | None | None |
| 20 | 49/M | CHOP, PUVA, radiotherapy, mustine | PD | 613 | Yes | None | None |
| 21 | 38/M | PUVA, α-IFN | SD | 1009 | No | None | None† |
| 22 | 57/F | CHOP ×3, methotrexate | PD | 805 | Yes | HTN | None† |
| 23 | 64/F | Steroids, CsA | CR | 750 | No | None | None |
| 24 | 54/F | Steroids, azathioprine, methotrexate, mycophenolate | CR | 210 | No | HTN | None |
| 25 | 57/F | Steroids, PUVA, extracorporeal phototherapy, chlorambucil | CR | 720 | No | None | None |
| 26 | 70/M | Steroids, PUVA | PR‡ | 360 | No | HTN | None |
| 27 | 86/M | Steroids, PUVA | PR‡ | 300 | No | None | None |
| 28 | 82/M | PUVA, chlorambucil, CsA, steroids | NR | 100 | No | None | None |
| 29 | 74/F | PUVA, DCF, steroids | NR | 100 | No | None | None |
| 30 | 60/F | PUVA, methotrexate, etoposide, CsA, DCF, steroids | PR | 450 | No | None | None |
Patient no. . | Age/sex . | Previous treatment . | Best response . | Cumulative alemtuzumab dose (mg) . | Previous ANTH . | Cardiac risks before alemtuzumab therapy . | Cardiac toxicity during or after*alemtuzumab therapy . |
|---|---|---|---|---|---|---|---|
| 1 | 73/M | Steroids, interferon, Tigason | CR | 1016 | No | MI 1998, Asthma | None |
| 2 | 73/M | Methotrexate, interferon, photophoresis, chlorambucil, steroids, fludarabine ×5 | PR | 1033 | No | Asthma, chronic bronchitis | None |
| 3 | 77/F | Methotrexate + 5FU ×9, PUVA | CR | 913 | No | HTN, CVL 1996 | None |
| 4 | 60/F | PUVA, CdA ×4, CHOP ×8, radiotherapy | PD | 563 | Yes | None | None |
| 5 | 52/M | Chlorambucil + steroids, fludarabine + cyclophosphamide + steroids | SD | 733 | No | None | None |
| 6 | 61/M | PUVA-photophoresis, α-IFN, methotrexate | CR | 1023 | No | None | None |
| 7 | 49/F | Local skin treatment | PR | 968 | No | None | None |
| 8 | 65/F | Methotrexate, steroids | CR | 334 | No | Cardiomyopathy | None |
| 9 | 72/F | PUVA, radiotherapy | PR | 1063 | No | None | None |
| 10 | 55/M | PUVA, steroids | PR | 1033 | No | None | None |
| 11 | 63/M | CHOP ×5, radiotherapy | PD | 373 | Yes | None | None |
| 12 | 77/F | Radiotherapy, vitamin A, PUVA, α-IFN, methotrexate | SD | 313 | No | Angina pectoris | None |
| 13 | 62/F | PUVA, photophoresis, steroids | CR | 876 | No | None | None |
| 14 | 63/F | PUVA, α-IFN, chlorambucil + steroids | CR | 1035 | No | None | None |
| 15 | 60/F | Chlorambucil + steroids, CHOP ×4, photophoresis | PD | 756 | Yes | CHF, nonsymptomatic mitral insuffiency | None |
| 16 | 56/M | PUVA, radiotherapy | CR | 1033 | No | None | None |
| 17 | 71/F | PUVA, photophoresis | PR | 1033 | No | Unknown | None† |
| 18 | 57/M | PUVA, steroids, methotrexate | PD | 1033 | No | None | None† |
| 19 | 56/F | Radiotherapy, α-IFN, chlorambucil + steroids, methotrexate | PD | 253 | No | None | None |
| 20 | 49/M | CHOP, PUVA, radiotherapy, mustine | PD | 613 | Yes | None | None |
| 21 | 38/M | PUVA, α-IFN | SD | 1009 | No | None | None† |
| 22 | 57/F | CHOP ×3, methotrexate | PD | 805 | Yes | HTN | None† |
| 23 | 64/F | Steroids, CsA | CR | 750 | No | None | None |
| 24 | 54/F | Steroids, azathioprine, methotrexate, mycophenolate | CR | 210 | No | HTN | None |
| 25 | 57/F | Steroids, PUVA, extracorporeal phototherapy, chlorambucil | CR | 720 | No | None | None |
| 26 | 70/M | Steroids, PUVA | PR‡ | 360 | No | HTN | None |
| 27 | 86/M | Steroids, PUVA | PR‡ | 300 | No | None | None |
| 28 | 82/M | PUVA, chlorambucil, CsA, steroids | NR | 100 | No | None | None |
| 29 | 74/F | PUVA, DCF, steroids | NR | 100 | No | None | None |
| 30 | 60/F | PUVA, methotrexate, etoposide, CsA, DCF, steroids | PR | 450 | No | None | None |
M indicates male; F, female; PUVA, psoralen-ultraviolet light; 5FU, 5-fluorouracil; IFN, interferon; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CdA, 2-chlorodeoxyadenosine; CsA, cyclosporine A; DCF, deoxycoformycin; SD, stable disease; PR, partial response; CR, complete response; PD, progressive disease; CVL, cerebral vascular lesion; HTN, hypertension; CHF, congestive heart failure; ANTH, anthracyclines; MI, myocardial infarction.
Within 6 months of therapy
No event during alemtuzumab therapy; however, event after end of therapy is unknown
Resolution of symptoms, but persistent erythroderma and skin infiltrates